Adoptive immunotherapy of esablished pulmonary metastases with LAK cells and recombinant interleukin-2

James J. Mulé, Suyu Shu, Susan L. Schwarz, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

The activation of human peripheral blood leukocytes or murine splenocytes with interleukin-2 (IL-2) generated cells that were lytic in vitro for a variety of fresh tumor cells. The adoptive transfer of such lymphokine-activated killer (LAK) cells to mice with established pulmonary sarcoma metastases was highly effective in reducing the number (and size) ofthese tumor nodules when combined with repeated injections of recombinant IL-2. These findings provide a rationale for clinical trials of the infusion of human LAK cells generated with recombinant IL-2 as well as Phase I trials of the infusion of recombinant IL-2 systemically into humans.

Original languageEnglish (US)
Pages (from-to)1487-1489
Number of pages3
JournalScience
Volume225
Issue number4669
DOIs
StatePublished - Jan 1 1984

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Adoptive immunotherapy of esablished pulmonary metastases with LAK cells and recombinant interleukin-2'. Together they form a unique fingerprint.

  • Cite this